26 Aug 2017

(27 votes)

Rigvir® Effectiveness: Timeline and Treatable Conditions

rigvir success

ECHO-7 virus in refrigerated Rigvir® vials

Rigvir® (abbreviated from Riga virus) is a virus contained in the intestines of children to fight cancer cells. An immunologist from Latvia prof. Aina Muceniece unveiled this specific feature of ECHO-7 virus in the middle of the 20th century followed by the invention of Rigvir®.

Does Rigvir Work?

Shortly after, first Rigvir® clinical trials took place in 1968. In the course of the research, 415 melanoma patients received intramuscular injections. The results showed that the malignant cells, which hadn’t been exposed to either chemotherapy or radiotherapy, began to disappear. Moreover, healthy cells of the patients’ surrounding tissues remained untouched.

2004 became a year of Rigvir® registration in the Latvian pharma market. However, the timeframe between 1968 and 2004 has been marked as a period of continuous Rigvir® clinical trials. On top of that, not only melanoma patients were involved, but also those diagnosed with:

  • Glioblastoma
  • Kidney cancer
  • Neuroendocrine tumours
  • Pancreatic cancer
  • Uterine and ovarian cancer
  • Prostate and bladder cancer
  • Sarcomas etc.

Now, why don’t we take a look at the functional principle of Rigvir®? You get a shot of the drug programmed to spot malignant cells in your body. After identifying them, Rigvir® reaches and destroys them leveraging the potential of your immune system to combat the tumor and its metastases.

Rigvir® Clinical Trials and How to Apply for Virotherapy in Latvia

Rigvir® statistics show:

  • 3-year survival rate for melanoma patients went up to 57-84% compared to the survival rate of patients who underwent surgery (46-58%)
  • 3-year survival rate for ocular melanoma patients constitutes 90%, and 5-year survival rate is 70%
  • 5-year survival rate for stage III stomach cancer patients increased to 47-60% compared to the survival rate of patients who faced surgery (24-33%)
  • 5-year survival rate for stage II-IV rectal cancer patients grew up to 71-78% compared to the survival rate of surgery patients (41-68%)

Rigvir Success Rate

A medical journal Melanoma Research published its findings about virotherapy in October 2015. It states that Rigvir® success rate is impressive: patients who applied virotherapy had 4-6 times more chances to survive.

Rigvir Side Effects. What are they?

Several cases of increased body temperature (up to 37.5°C or 99.5°F) have been reported, but most patients showed no Rigvir® side effects.

As there’s no all-in-one solution and each cancer case is individual, the first step to start your virotherapy course would be to collect your most recent medical reports. Then the oncologist at Global Virotherapy Cancer Clinic in Latvia will assess your case within 48-72 hours at no charge and inform you whether you can be qualified for Rigvir® therapy.

The medical reports and scans necessary to apply for the virotherapy in Latvia include:

  • Epicrisis
  • CT and MRI reports (no images required)
  • Histopathological and cytological findings
  • Complete blood count not older than 2 weeks + WBC
  • Blood biochemistry (ALT, creatinine etc.)

 If you get qualified for the virotherapy course, the support agent will get in touch with you to explain more about a 7-day Complex Virotherapy Service Package at the coast of the Baltic Sea, Latvia. Both the medical team and scenic landscape work together to improve your mental and physical health.

The package consists of:

  • test whether you’re not allergic to Rigvir® and 3 Rigvir® injections
  • consultations with the oncologist and immunologist to track your progress
  • personalized nutrition plan
  • several acupuncture, art therapy, psychotherapy sessions
  • follow-up plan for the upcoming 3 months including the required number of Rigvir® vials (these vials are charged additionally)
  • airport transfers
  • accommodation

If you choose standard accommodation, the whole program would cost you EUR 7,000 whereas if you opt for a superior room, the price would be EUR 10,000.

rigvir success rigvir success rigvir successrigvir successrigvir successrigvir success

After a 7-day Complex Virotherapy Service Package including the three-month follow-up program which is carried out after you return to your home country, you may choose between two follow-up programs: Onsite Follow-Up Package or Remote Follow-Up Package.

Onsite Follow-Up Package implies that you arrive in Latvia once again for three days and take advantage of:

  • personal nutrition plan
  • follow-up plan for the upcoming 3 months including the required number of Rigvir® vials (these vials are charged additionally)
  • a meeting with one of the specialists – art therapist, physiotherapist, psychologist, or acupuncture specialist

The price for this package in EUR 3,000 excluding the cost of Rigvir© vials.

In case you’d rather have your virotherapy at home, choose Remote Follow-Up Package which includes:

  • 30-minutes Skype consultation with an oncologist, who’ll analyze your previous results and give further recommendations
  • monthly patient support
  • another three-month follow-up plan
  • nutrition plan

The package costs EUR 2,100 while Rigvir© vials are also purchased separately.



List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
  3. Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.